TransCode Therapeutics, Inc.
RNAZ
$6.73
-$0.27-3.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.77M | 5.46M | 5.00M | 5.38M | 5.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.19M | 17.05M | 14.65M | 15.54M | 15.66M |
| Operating Income | -19.19M | -17.05M | -14.65M | -15.54M | -15.66M |
| Income Before Tax | -34.44M | -27.13M | -24.60M | -25.51M | -16.76M |
| Income Tax Expenses | 226.10K | -- | -- | -- | -- |
| Earnings from Continuing Operations | -34.66 | -27.13 | -24.60 | -25.51 | -16.76 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.66M | -27.13M | -24.60M | -25.51M | -16.76M |
| EBIT | -19.19M | -17.05M | -14.65M | -15.54M | -15.66M |
| EBITDA | -19.12M | -17.00M | -14.60M | -15.47M | -15.57M |
| EPS Basic | -97.60 | -362.35 | -502.59 | -497.46 | -427.30 |
| Normalized Basic EPS | -54.81 | -225.58 | -313.23 | -310.02 | -266.18 |
| EPS Diluted | -97.60 | -362.35 | -502.59 | -497.46 | -427.30 |
| Normalized Diluted EPS | -54.81 | -225.58 | -313.23 | -310.02 | -266.18 |
| Average Basic Shares Outstanding | 2.75M | 1.86M | 1.04M | 209.30K | 37.00K |
| Average Diluted Shares Outstanding | 2.75M | 1.86M | 1.04M | 209.30K | 37.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |